Sunday, November 02, 2008
Informed Consent Revisited: A Doctrine in the Service of Cancer Care - The Oncologist
Informed Consent Revisited: A Doctrine in the Service of Cancer Care -- Schachter and Fins 13 (10): 1109 -- The Oncologist
Empathetic and attentive interest in patients facilitates an understanding about patients' physiological and psychological needs. Significantly, it enables the physician to contextualize the patient's decision within the patient's moral and values framework. If there is a paradox in all of this, it is that the ideal of informed consent rests as much in the physician educating the patient as it does in the patient educating the physician.
The Edmonton symptom assessment system-what do patients think? [Support Care Cancer. 2008]
The Edmonton symptom assessment system-what do pat...[Support Care Cancer. 2008] - PubMed Result
"Patients expressed a need to emphasize the timeframe as 'now'."
Interval debulking surgery for advanced epithelial ovarian cancer
Interval debulking surgery for advanced epithelial ovarian cancer
Plain language summary
Interval debulking surgery for advanced epithelial ovarian cancer
"Ovarian cancer frequently presents at an advanced stage so it may not be possible to surgically remove all the tumours. Several cycles of chemotherapy are generally given after primary surgery. Secondary surgery, performed after a few cycles of chemotherapy before proceeding to further cycles of chemotherapy, is called interval debulking surgery (IDS). This review compared the survival of patients with advanced epithelial ovarian cancer, who had IDS performed between cycles of chemotherapy after primary surgery with survival of patients who had conventional treatment (primary debulking surgery and adjuvant chemotherapy). It found similar survival in patients who did and did not receive IDS. No adequate information regarding adverse effects was available. Data on quality of life (QOL) of the patients were also inconclusive."
The American Journal of Surgical Pathology - Abstract: Volume 32(11) November 2008 p 1667-1674 Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated
Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data.
free full text: Loss of DNA Mismatch Repair Protein hMSH6 (one Lynch Syndrome gene) in Ovarian Cancer is Histotype-Specific
Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific
Conclusions:
These results underscore the importance of identifying the correct HNPCC-associated tumors and genes toward the recognition of affected families that may develop ovarian carcinoma as well as appropriate clinical surveillance. We found negative hMSH6 protein expression in several histologic subtypes of ovarian carcinoma, particularly in clear cell, endometrioid, and mucinous carcinoma, suggesting that loss of hMSH6 function may participate in the genesis of these subtypes of cancer. However, loss of hMSH6 protein expression did not predict overall survival, and it was not associated with disease stage, tumor grade, patient age or family history of cancer.
Subscribe to:
Posts
(
Atom
)
Posts
